Concord Biotech Limited Financial Flexibility Index
Concord Biotech Limited financial flexibility index. Concord Biotech Limited (CONCORDBIO) has a Financial Flexibility Index of 1.62x as of March 2025. Free cash flow of Rs3.59 Billion (operating CF Rs2.47 Billion minus capex Rs1.11 Billion) represents 2% of total liabilities (Rs2.22 Billion). See CONCORDBIO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of Concord Biotech Limited (2020–2025)
Financial flexibility index of Concord Biotech Limited from 2020 to 2025. Historical Financial Flexibility Index trend for Concord Biotech Limited across 6 annual periods. Check CONCORDBIO cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Concord Biotech Limited Financial Flexibility Index by Year (2020–2025)
Concord Biotech Limited financial flexibility index by year from 2020 to 2025. Year-by-year free cash flow to debt coverage for Concord Biotech Limited. For the full cash flow conversion analysis, see Concord Biotech Limited cash conversion from operations.
| Year | Flexibility Index | Free Cash Flow (INR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.62x | Rs3.59 Billion | Rs2.47 Billion | Rs2.22 Billion | ▼ -19.8% |
| 2024 | 2.02x | Rs3.51 Billion | Rs2.65 Billion | Rs1.74 Billion | ▲ +15.5% |
| 2023 | 1.75x | Rs3.91 Billion | Rs2.46 Billion | Rs2.24 Billion | ▲ +0.8% |
| 2022 | 1.73x | Rs3.63 Billion | Rs2.07 Billion | Rs2.10 Billion | ▼ -14.5% |
| 2021 | 2.03x | Rs3.71 Billion | Rs1.67 Billion | Rs1.83 Billion | ▲ +11.1% |
| 2020 | 1.82x | Rs3.10 Billion | Rs1.55 Billion | Rs1.70 Billion | — |